Depletion of Cks1 and Cks2 expression compromises cell proliferation and enhance chemotherapy-induced apoptosis in HepG2 cells

Oncology Reports

Volumn 35, Issue 1, 2016, Pages 26-32

  Lin, Lingqing ^a   Fang, Zanxi ^a   Lin, Huayue ^a   You, Hanyu ^a   Wang, Jiajia ^a   Su, Yuanhui ^a   Wang, Fen ^c   Zhang, Zhong Ying ^a,b  

^a ZHONGSHAN HOSPITAL OF XIAMEN UNIVERSITY   (China)

^b XIAMEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

Apoptosis; Cyclin dependent kinase subunit; Hepatocellular carcinoma; Proliferation

Indexed keywords

CISPLATIN; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; GLYCOGEN SYNTHASE KINASE 3BETA; MESSENGER RNA; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CARRIER PROTEIN; CELL CYCLE PROTEIN; CKS1B PROTEIN, HUMAN; CKS2 PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE; GLYCOGEN SYNTHASE KINASE 3; GSK3B PROTEIN, HUMAN;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CYCLE; CELL DENSITY; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; CULTURE MEDIUM; DOWN REGULATION; ENZYME ACTIVITY; ENZYME PHOSPHORYLATION; FLOW CYTOMETRY; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; RNA INTERFERENCE; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENETICS; HEP-G2 CELL LINE; LIVER TUMOR; METABOLISM; PHOSPHORYLATION; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CARRIER PROTEINS; CDC2-CDC28 KINASES; CELL CYCLE PROTEINS; CELL PROLIFERATION; CISPLATIN; GLYCOGEN SYNTHASE KINASE 3; GLYCOGEN SYNTHASE KINASE 3 BETA; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; UP-REGULATION;

EID: 84954042660     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2015.4372     Document Type: Article

References (17)

1. Richardson HE, Stueland CS, Thomas J, Russell P and Reed SI: Human cDNAs encoding homologs of the small p34Cdc28/Cdc2-associated protein of Saccharomyces cerevisiae and Schizosaccharomyces pombe. Genes Dev 4: 1332-1344, 1990.
2. Wang JJ, Fang ZX, Ye HM, You P, Cai MJ, Duan HB, Wang F and Zhang ZY: Clinical significance of overexpressed cyclin-dependent kinase subunits 1 and 2 in esophageal carcinoma. Dis Esophagus 26: 729-736, 2013.
3. Lan Y, Zhang Y, Wang J, Lin C, Ittmann MM and Wang F: Aberrant expression of Cks1 and Cks2 contributes to prostate tumorigenesis by promoting proliferation and inhibiting programmed cell death. Int J Cancer 123: 543-551, 2008.
4. Yu M, Zhong M and Qiao Z: Expression and clinical significance of cyclin kinase subunit 2 in colorectal cancer. Oncol Lett 6: 777-780, 2013.
5. Lee SW, Kang SB, Lee DS and Lee JU: Akt and Cks1 are related with lymph node metastasis in gastric adenocarcinoma. Hepatogastroenterology 60: 932-937, 2013.
6. Tanaka F, Matsuzaki S, Mimori K, Kita Y, Inoue H and Mori M: Clinicopathological and biological significance of CDC28 protein kinase regulatory subunit 2 overexpression in human gastric cancer. Int J Oncol 39: 361-372, 2011.
7. Shen DY, Zhan YH, Wang QM, Rui G and Zhang ZM: Oncogenic potential of cyclin kinase subunit-2 in cholangiocarcinoma. Liver Int 33: 137-148, 2013.
8. Shen DY, Fang ZX, You P, Liu PG, Wang F, Huang CL, Yao XB, Chen ZX and Zhang ZY: Clinical significance and expression of cyclin kinase subunits 1 and 2 in hepatocellular carcinoma. Liver Int 30: 119-125, 2010.
9. Li F, Zhao C and Wang L: Molecular-targeted agents combination therapy for cancer: Developments and potentials. Int J Cancer 134: 1257-1269, 2014.
10. Ricke J, Bulla K, Kolligs F, Peck-Radosavljevic M, Reimer P, Sangro B, Schott E, Schütte K, Verslype C, Walecki J, et al.; SORAMIC study group: Safety and toxicity of radioembolization plus sorafenib in advanced hepatocellular carcinoma: Analysis of the European multicentre trial SORAMIC. Liver Int 35: 620-626, 2015.
11. Zhu AX, Duda DG, Ancukiewicz M, Di Tomaso E, Clark JW, Miksad R, Fuchs CS, Ryan DP and Jain RK: Exploratory analysis of early toxicity of sunitinib in advanced hepatocellular carcinoma patients: Kinetics and potential biomarker value. Clin Cancer Res 17: 918-927, 2011.
12. Ganoth D, Bornstein G, Ko TK, Larsen B, Tyers M, Pagano M and Hershko A: The cell-cycle regulatory protein Cks1 is required for SCF(Skp2)-mediated ubiquitinylation of p27. Nat Cell Biol 3: 321-324, 2001.
13. Kita Y, Nishizono Y, Okumura H, Uchikado Y, Sasaki K, Matsumoto M, Setoyama T, Tanoue K, Omoto I, Mori S, et al: Clinical and biological impact of cyclin-dependent kinase subunit 2 in esophageal squamous cell carcinoma. Oncol Rep 31: 1986-1992, 2014.
14. Franke TF, Kaplan DR and Cantley LC: PI3K: Downstream AKTion blocks apoptosis. Cell 88: 435-437, 1997.
15. Burgering BM and Coffer PJ: Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction. Nature 376: 599-602, 1995.
16. Franke TF, Yang SI, Chan TO, Datta K, Kazlauskas A, Morrison DK, Kaplan DR and Tsichlis PN: The protein kinase encoded by the Akt proto-oncogene is a target of the PDGF-activated phosphatidylinositol 3-kinase. Cell 81: 727-736, 1995.
17. Hajduch E, Litherland GJ and Hundal HS: Protein kinase B (PKB/Akt) - a key regulator of glucose transport? FEBS Lett 492: 199-203, 2001.